These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 11061536

  • 1. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.
    Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff B, Murphy M, Thomas E, Robinson S, Foale R, Johnston DG.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3762-9. PubMed ID: 11061536
    [Abstract] [Full Text] [Related]

  • 2. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance.
    Beshyah SA, Henderson A, Niththyananthan R, Skinner E, Anyaoku V, Richmond W, Sharp P, Johnston DG.
    J Clin Endocrinol Metab; 1995 Feb; 80(2):356-63. PubMed ID: 7852490
    [Abstract] [Full Text] [Related]

  • 3. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.
    Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J.
    J Clin Endocrinol Metab; 1995 Jan; 80(1):153-9. PubMed ID: 7829604
    [Abstract] [Full Text] [Related]

  • 4. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults.
    Beshyah SA, Freemantle C, Shahi M, Anyaoku V, Merson S, Lynch S, Skinner E, Sharp P, Foale R, Johnston DG.
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):73-84. PubMed ID: 7889635
    [Abstract] [Full Text] [Related]

  • 5. Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults.
    Al-Shoumer KA, Page B, Thomas E, Murphy M, Beshyah SA, Johnston DG.
    Eur J Endocrinol; 1996 Nov; 135(5):559-67. PubMed ID: 8980158
    [Abstract] [Full Text] [Related]

  • 6. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency.
    Gómez JM, Sahún M, Vila R, Domènech P, Catalina P, Soler J, Badimón L.
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):632-9. PubMed ID: 16712664
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [Abstract] [Full Text] [Related]

  • 8. The effects on insulin action in adult hypopituitarism of recombinant human GH therapy individually titrated for six months.
    McConnell EM, Atkinson AB, Ennis C, Hadden DR, McCance DR, Sheridan B, Bell PM.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5342-7. PubMed ID: 11701703
    [Abstract] [Full Text] [Related]

  • 9. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients.
    Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G.
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3954-61. PubMed ID: 16895963
    [Abstract] [Full Text] [Related]

  • 10. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.
    Franco C, Johannsson G, Bengtsson BA, Svensson J.
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4408-14. PubMed ID: 16940452
    [Abstract] [Full Text] [Related]

  • 11. The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults.
    Sverrisdóttir YB, Elam M, Caidahl K, Söderling AS, Herlitz H, Johannsson G.
    J Hypertens; 2003 Oct; 21(10):1905-14. PubMed ID: 14508197
    [Abstract] [Full Text] [Related]

  • 12. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia.
    Follin C, Thilén U, Ahrén B, Erfurth EM.
    J Clin Endocrinol Metab; 2006 May; 91(5):1872-5. PubMed ID: 16522695
    [Abstract] [Full Text] [Related]

  • 13. Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment.
    Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I.
    J Clin Endocrinol Metab; 1995 Feb; 80(2):659-66. PubMed ID: 7852533
    [Abstract] [Full Text] [Related]

  • 14. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
    Cenci MC, Conceição FL, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E, Vaisman M.
    Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
    [Abstract] [Full Text] [Related]

  • 15. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Góth MI, Wilton P, Koltowska-Häggström M.
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database.
    Monson JP, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stâhl E, Thorén M, Westberg B, Wilton P, Wüster C.
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):281-9. PubMed ID: 10971444
    [Abstract] [Full Text] [Related]

  • 17. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database.
    Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, Strasburger CJ, Bouillon R, Crowe B, Selander K, Valle D, Lamberts SW, Hypoptiuitary Control and Complications Study International Advisory Board.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1600-6. PubMed ID: 11932289
    [Abstract] [Full Text] [Related]

  • 18. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
    Filipsson Nyström H, Barbosa EJ, Nilsson AG, Norrman LL, Ragnarsson O, Johannsson G.
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
    [Abstract] [Full Text] [Related]

  • 19. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency.
    Elgzyri T, Castenfors J, Hägg E, Backman C, Thorén M, Bramnert M.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):113-22. PubMed ID: 15212653
    [Abstract] [Full Text] [Related]

  • 20. Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.
    Joaquin C, Aguilera E, Granada ML, Pastor MC, Salinas I, Alonso N, Sanmartí A.
    Eur J Endocrinol; 2008 Apr; 158(4):483-90. PubMed ID: 18362295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.